EVER PHARMA

STROKE

TBI

DEMENTIA

Published in
Stroke

Stroke. January 2016;47:151-159
Muresanu D.F. et al.

Regain full independence with Cerebrolysin

Effective pharmacological treatment for **STROKE** patients

Muresanu D.F. et al., **C**erebrolysin **A**nd **R**ecovery after **S**troke (CARS), Stroke 2016; 47:151-159

CARS results - Cerebrolysin in patients after STROKE

- Improvement of motor functions
- Early recovery
- Regain full independence
- Increase quality of life

Cerebrolysin®

Reconnecting Neurons.
Empowering for Life.

Cerebrolysin improves quality of life

Significant improvement of mRS* score with Cerebrolysin

→ 3 times more patients (+200%) are able to live a fully independent life

Cerebrolysin 42.3% vs. Placebo 14.9%
of patients without symptoms or no significant disability



Figure: Shift in mRS scale from early rehabilitation to Cerebrolysin with early rehabilitation

- A favorable outcome was shown in the mRS score
- After 90 days post-stroke **42.3% of patients** gained full independence (mRS score 0-1) in the Cerebrolysin group while only 14.9% of patients reached the same level in the placebo group

full article

Published in
Stroke

Stroke. January 2016;47:151-159
Muresanu D.F. et al.

Titel	**C**erebrolysin **A**nd **R**ecovery after **S**troke (CARS) – A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial
Patients	**104 Cerebrolysin group + 104 Placebo group = 208 patients in total** Cerebrolysin group = Cerebrolysin + Standard rehabilitation therapy Placebo group = Saline + Standard rehabilitation therapy
Treatment	**30ml/day for 21 days** followed by 69 days treatment-free period Primary endpoint = ARAT score on day 90

* mRS = Modified Rankin Scale

ABBREVIATED PRESCRIBING INFORMATION. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of porcine brain-derived peptide preparation (Cerebrolysin concentrate) in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: Organic, metabolic and neurodegenerative disorders of the brain, especially senile dementia of Alzheimer's type - Post-apoplectic complications - Craniocerebral trauma; post-operative trauma, cerebral contusion or concussion. Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.

CERE/A/01/2016/8